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Key questions
What is already known?
 ► The evidence on risk factors for death in children >5 
years with community-acquired pneumonia is ex-
tremely limited, and definitions for what constitutes 
severe disease are not standardised.
 ► In fact, there are no studies from low-income or mid-
dle-income countries that report risk factors for in-
patient pneumonia mortality specifically in children 
>5 years.
 ► As such, data to inform age-specific case manage-
ment in low-income and middle-income settings do 
not exist.
What are the new findings?
 ► Pneumonia mortality in this cohort is high (7.9%).
 ► The risk factors for pneumonia mortality in children 
>5 years are broadly similar to those identified for 
children under 5 years.
 ► These include: the presence of severe pallor, re-
duced level of consciousness, mild/moderate pallor, 
central cyanosis, older age (>9 years), respiratory 
rate >30/min, inability to eat or drink, HIV and se-
vere malnutrition.
What do the new findings imply?
 ► While these data do not constitute formal evidence 
that using these patient features to indicate high risk 
of mortality would save lives, they do make it clear 
that we need to better understand the characteris-
tics of children presenting with possible pneumonia 
at all levels of the health system and that there is a 
need for research to explore the underlying factors 
that account for this.
AbsTrACT
Introduction There were almost 1 million deaths in 
children aged between 5 and 14 years in 2017, and 
pneumonia accounted for 11%. However, there are no 
validated guidelines for pneumonia management in older 
children and data to support their development are limited. 
We sought to understand risk factors for mortality among 
children aged 5–14 years hospitalised with pneumonia in 
district-level health facilities in Kenya.
Methods We did a retrospective cohort study using data 
collected from an established clinical information network of 
13 hospitals. We reviewed records for children aged 5–14 
years admitted with pneumonia between 1 March 2014 and 
28 February 2018. Individual clinical signs were examined for 
association with inpatient mortality using logistic regression. 
We used existing WHO criteria (intended for under 5s) to 
define levels of severity and examined their performance in 
identifying those at increased risk of death.
results 1832 children were diagnosed with pneumonia 
and 145 (7.9%) died. Severe pallor was strongly associated 
with mortality (adjusted OR (aOR) 8.06, 95% CI 4.72 to 
13.75) as were reduced consciousness, mild/moderate 
pallor, central cyanosis and older age (>9 years) (aOR >2). 
Comorbidities HIV and severe acute malnutrition were 
also associated with death (aOR 2.31, 95% CI 1.39 to 3.84 
and aOR 1.89, 95% CI 1.12 to 3.21, respectively). The 
presence of clinical characteristics used by WHO to define 
severe pneumonia was associated with death in univariate 
analysis (OR 2.69). However, this combination of clinical 
characteristics was poor in discriminating those at risk of 
death (sensitivity: 0.56, specificity: 0.68, and area under 
the curve: 0.62).
Conclusion Children >5 years have high inpatient 
pneumonia mortality. These findings also suggest that the 
WHO criteria for classification of severity for children under 5 
years do not appear to be a valid tool for risk assessment in 
this older age group, indicating the urgent need for evidence-
based clinical guidelines for this neglected population.
InTroduCTIon
In 2017, there were still an estimated 
6.3 million child deaths globally, of which, 
almost 1 million occurred in children aged 
5–14 years.1 According to a recent review 
of mortality trends in this older age group, 
98% of deaths occurred in low-income or 
middle-income countries (LMICs) and 55% 
occurred in sub-Saharan Africa—an increase 
from 36% in 1990.1 2 In sub-Saharan Africa, 
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the probability of a child aged 5 years dying between 
the ages of 5 and 15 years was reported at 18.4 deaths 
per 1000 children, which is 17 times higher than in 
high-income countries.2 Historically, global initiatives to 
reduce child mortality have focused on children under 5 
years. This was reflected in the United Nation’s Millen-
nium Development Goals and again in their Sustainable 
Development Goals (2015). In contrast, morbidity and 
mortality among older children and adolescents have 
received little attention.
The limited data available suggest that lower respiratory 
tract infections account for a significant proportion of 
deaths for children aged 5–14 years.3 4 However, the WHO 
pneumonia case-management guidelines are specific to 
children under 5 years.5 The WHO’s Integrated Manage-
ment of Adolescent and Adult Illness (IMAI) initiative 
does provide guidance and training material for older 
patients,6 but these are based on limited evidence, and 
group all those aged over 5 years into just one category. 
Children over 5 years may require specific management, 
for example, some data suggest that they are more likely 
to present with atypical infection.7 However, in low-re-
source settings, age-specific evidence to inform clinical 
risk assessment and treatment policies is lacking, and is 
much needed to improve quality of care.
In this analysis, we describe the clinical characteristics 
and comorbidities of children aged 5–14 years admitted 
to district-level hospitals in Kenya with pneumonia, and 
assess risk factors for death. We highlight clinical features 
that may improve risk assessment and examine the 
performance of the existing WHO criteria (intended for 
under 5s) for differentiating children at risk of death to 
inform potential future studies on appropriate guidelines 
in this age group. Finally, we explore current prescription 
patterns in older children for whom no national guid-
ance is available in Kenya.
MeTHods
study design, setting and population
We did a retrospective cohort study using routine clinical 
data from an established Clinical Information Network 
(CIN) in Kenya and examined the association between 
individual clinical characteristics and inpatient mortality 
using logistic regression. We reviewed inpatient records 
for all children age 5–14 years admitted to hospital over 
a 4-year period—1 March 2014 to 28 February 2018—
with a clinician diagnosis of pneumonia at the point of 
discharge or death. Children 15 years and over were 
excluded, as hospital policies would dictate that these 
patients are admitted under adult care.
The CIN was established in September 2013 to foster 
better generation and use of clinical information and 
improve quality of care.8 9 The network consists of 13 
purposely selected public county hospitals, situated in 
regions of high and low malaria transmission, which are 
representative of district-level health facilities in Kenya. 
They have limited diagnostic capacity, including poor 
access to pulse oximetry and microbiological investiga-
tion, and diagnoses are generally made by junior clini-
cians who review all children requiring admission and 
prescribe their initial treatment. As a component of the 
network intervention, quality of inpatient care is peri-
odically audited against national protocols,10 which are 
adapted from the WHO guidelines.5 11 This is fed back to 
the hospitals for quality improvement,12 although given 
the lack of clear guidelines for children over 5 years, this 
feedback is limited to under 5 conditions. Routine data 
collected includes: biodata, clinical information, history 
and examination findings, admission and discharge 
diagnoses, investigations, treatments prescribed and 
outcomes. All clinical variables are collected at admis-
sion, discharge diagnosis and outcome are collected at 
the point of discharge (including death) and investiga-
tions (malaria and HIV) are captured at various points 
during the inpatient stay.
Patient and public involvement
Not applicable as this study was a secondary analysis of 
routinely collected data.
Pneumonia severity
We examined individual clinical risk factors for associa-
tion with mortality (detailed in the ‘Statistical analysis’ 
section). To explore whether the existing WHO criteria 
were useful in discriminating risk in this older cohort, we 
used the available information on clinical characteristics 
to define two levels of severity based on the 2013 WHO 
pneumonia guidelines for use in children under 5 years.5 
The details of our approach are provided in table 1. We 
were unable to include oxygen saturations (<90%) in 
the study definition for severe disease, as pulse oximetry 
was not consistently available in the CIN hospitals. The 
WHO guidelines for children under 5 years and the IMAI 
guidelines are also presented in table 1 for comparison.
Comorbidities
We identified children with comorbidities using a combi-
nation of documented discharge diagnoses, clinical char-
acteristics at presentation and laboratory data (table 2). 
We examined HIV, sickle cell disease, chronic neuro-
logical disorder, asthma, cardiac disease, renal disease, 
severe malnutrition, malaria, sepsis, acute neurological 
disease and diarrhoea with dehydration for association 
with death. To identify children with severe malnutrition 
we used the clinician diagnosis, or the presence of any one 
of: oedema (not attributable to renal disease); mid-upper 
arm circumference (MUAC) ≤115 mm; weight-for-height 
z (WHZ) score ≤−3 SD. We were unable to use data for 
MUAC and height alone to identify children with malnu-
trition as these measures were poorly recorded (missing 
in 60% and 76% of cases, respectively).
Treatment
In the absence of treatment guidelines for children 
aged 5–14 years, we used available information on 
admission prescriptions to describe antibiotic use for 
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Table 1 WHO under 5, IMAI and operational study definitions of pneumonia
Clinical signs
Adapted from WHO Pocket 
Book of Hospital Care for 
Children for children under 5 
years5
Clinical signs
Adapted from the IMAI 
District Clinician manual 
for adolescents and 
adults*6
Clinical signs
Operational study definitions
Severe pneumonia
Recommended treatment: 
intravenous penicillin with 
gentamicin†
History of cough or difficulty 
breathing and any one of:
 ► Oxygen saturations <90%, or 
central cyanosis
 ► Severe respiratory distress
 ► General danger sign (inability 
to breast feed or drink, 
lethargy or reduced level of 
consciousness, convulsions)
Any one of:
 ► Appears obstructed
 ► Central cyanosis
 ► Severe respiratory 
distress
AND any one of:
 ► Oxygen saturations 
<90%
 ► Respiratory rate >30/
min
 ► Fever or suspected 
infection
 ► Signs of severe 
respiratory distress
Pneumonia diagnosis and 
any one of:
 ► Central cyanosis
 ► Severe respiratory distress 
(grunting, stridor)
 ► General danger sign 
(inability to feed or 
drink, reduced level of 
consciousness)
Non-severe pneumonia 
Recommended treatment: 
intravenous penicillin or oral 
amoxicillin†
History of cough or difficulty 
breathing and
 ► Fast breathing (for age) or
 ► Chest indrawing
 ► Without any of the criteria for 
severe pneumonia
 ► Signs and symptoms 
of pneumonia without 
meeting the criteria for 
severe pneumonia
 ► Pneumonia diagnosis 
without meeting the criteria 
for severe pneumonia
*The assessment for severe pneumonia comes after an initial ‘quick check’ using the airway, breathing, circulation approach to identify 
patients presenting with emergency signs and is not intended for those with features of shock.
†These are the recommendations as per the WHO Pocket Book of Hospital Care for Children.5
IMAI, Integrated Management of Adolescent and Adult Illness.
Table 2 Study classification of comorbidities
Comorbidity Study classification
Chronic neurological disorder, asthma, cardiac 
disease, renal disease, sepsis
Documented clinician diagnosis.
Sickle cell disease, malaria Documented clinician diagnosis or any positive laboratory result.
HIV Documented clinician diagnosis or any positive HIV test result (serology or 
PCR).
Severe malnutrition Documented severe malnutrition clinician diagnosis or oedema, MUAC 
<115 mm, WHZ ≤−3 SD.
Acute neurological disorder Documented meningitis clinician diagnosis of meningitis or history of 
convulsions or altered level of consciousness based on the AVPU scale.
Diarrhoea with dehydration Documented clinician dehydration diagnosis and history of diarrhoea.
AVPU, alert, verbal, pain, unresponsive; MUAC, mid-upper arm circumference; WHZ, weight-for-height z score.
our cohort and explore whether children were treated 
as per the WHO pneumonia guidelines for children 
under 5 years.5 For the purpose of this latter analysis 
only, children who were re-admitted (within 30 days of 
the presenting illness episode) or were referred from 
another hospital, and those with HIV or severe malnu-
trition were excluded, as WHO recommendations for 
first-line antibiotic therapy are not directly applicable 
to these groups. WHO under 5 guidelines recommend 
that children presenting with signs of severe pneumonia 
should receive intravenous penicillin and gentamicin, 
and those with non-severe pneumonia should receive 
oral amoxicillin or, in pre-2013 guidelines, intravenous 
penicillin monotherapy (table 1). In our setting, amik-
acin is often used when gentamicin is unavailable so the 
two were combined under the heading aminoglycosides. 
We were unable to account for the effect of antibiotic 
treatment on outcome because we only had information 
on prescriptions on admission which does not reflect what 
was actually administered, nor any changes to treatment 
made during admission.
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data management
Within the CIN, clinician diagnoses are documented 
according to the 10th Revision of International Statistical 
Classification of Diseases and Related Health Problems 
system. For pragmatic reasons, the research team reclassi-
fied these diagnoses to fit one of 38 predefined categories. 
Clinical information is captured through standardised, 
Ministry of Health approved, Paediatric Admission Record 
forms. These are used by clinicians and form part of the 
medical records, they prompt the clinician for information 
with a series of checkboxes and free text options. At the 
end of each admission episode (discharge from hospital 
or death), data are abstracted directly from the patient’s 
hospital records—medical notes, nursing charts, treat-
ment charts and laboratory reports—and are recorded 
directly into the primary data collection tool (developed 
in Research Electronic Data Capture).13 Data are entered 
retrospectively at each hospital by a trained clerk with 
remote support from a central data team. This process 
has automated point of entry error checks and regular 
external data quality assurance. Descriptive analyses on 
the magnitude and nature of the data errors captured 
from this network indicate that errors are uncommon.14 
In some hospitals with high work load, a minimum set of 
data is collected for a random sample of patients. These 
data only include variables that are required for standard 
health system reports and have limited clinical informa-
tion, therefore, these patients were not included in this 
analysis. A more detailed description of the methodology 
for collection and cleaning of hospital data within the CIN 
is described elsewhere.15
Our findings were reported in keeping with the 
Strengthening the Reporting of Observational Studies 
in Epidemiology statement guidelines,16 and Ethical 
approval for the use ofde-identified routine data was 
provided by the parent study of the CIN from theKenya 
Medical Research Institute (KEMRI) Scientific and Ethics 
Committee(SERU), approval numbers SSC 1746 and 
2771). The Ministry of Health andparticipating hospitals 
also gave their permission.
statistical analysis
Continuous variables were reported as mean (SD) or 
median (IQR) as appropriate, categorical data were 
summarised as proportions. We used χ2 test to determine 
associations between categorical variables, except where 
the sample size was ≤5 where Fisher’s exact test was applied. 
Univariate associations with mortality were calculated for 
demographic and clinical characteristics, and comorbidi-
ties. Factors found to be associated with mortality in univar-
iate analysis (p<0.1) and with <20% missing data were then 
considered for inclusion in the multivariate models. Age 
and sex were included a priori and hospital identity was 
included as a random effect. In model 1, clinical character-
istics were examined for association with death. In model 
2, information on HIV, malaria and severe malnutrition 
was incorporated. These comorbidities were agreed a 
priori and were selected due to their clinically important 
impact on outcome and because they can be diagnosed 
early during the admission and could feasibly form part of 
a clinical risk assessment strategy. The models were built 
sequentially to mirror information available to the clinician 
from the time the child is first assessed to the availability of 
rapid diagnostic test results and assessment of nutritional 
status. At each stage, variables for inclusion in the multivar-
iate models were reviewed and excluded if they expressed 
collinearity with another variable. The following interac-
tions were also examined: malaria and pallor; age and HIV; 
age and pallor.
We performed a separate analysis to explore the effect 
of nutritional status defined by weight-for-age z scores 
(WAZ) on clinical outcome (online supplementary mate-
rial model 3). WAZ scores are often used to describe nutri-
tional status in studies of children under 5 years,17 18 and 
these variables (weight and age) are well recorded in our 
data. We calculated WAZ scores using WHO child growth 
standards,19 excluding children over 10 years where 
there are no reference standards (WAZ scores are not 
reliable in the context of pubertal growth spurts).19 We 
also performed an adjusted subgroup analysis of children 
from non-malaria endemic regions to explore the effect 
of pallor on outcome in a population where malaria is 
unlikely to account for anaemia (online supplementary 
material model 4).
To handle missing data, we performed multiple impu-
tation with chained equations for variables with <20% 
missingness. We generated 30 imputed datasets, each 
with 100 iterations, under the assumption that data were 
missing at random. Finally, we calculated the sensitivity, 
specificity, positive and negative likelihood ratios, and area 
under the receiver operator curve in predicting death for 
severe pneumonia and for the clinical characteristics that 
were associated with mortality in adjusted analyses (online 
supplementary table 1). All statistical analyses were done 
using R statistical computing software V.3.4.4.20
resulTs
There were 88 794 children aged >1 month to <15 years 
admitted to the study hospitals between 1 March 2014 and 
28 February 2018, 17 923 (20.2%) were over 5 years. Of 
those over 5 years, 2096 (11.7%) had a discharge diagnosis 
of pneumonia. Two hundred sixty-four patient records were 
randomised to have minimum data captured. Therefore, 
analyses included 1832 children (figure 1). The median 
age of the study population was 84 months (IQR 66–108) 
and the majority (80%) of children in the study were aged 
5–9 years (figure 2). Hospital location was available for all 
patients and 849 (46.3%) were admitted to hospitals in 
high malaria transmission regions of Kenya. Clinical char-
acteristics are shown in table 3.
Using the predefined study criteria, we assigned a 
severity category to 1799 (98.2%) patients whose records 
had adequate documentation of clinical signs. On the 
basis of clinical characteristics, we identified 588 (32.7%) 
with severe pneumonia, younger children (aged 5–9 
Macpherson L, et al. BMJ Global Health 2019;4:e001715. doi:10.1136/bmjgh-2019-001715 5
BMJ Global Health
Figure 1 Age distribution (years) of children admitted to the 
study hospitals with pneumonia.
Figure 2 Age distribution (years) of children admitted to the 
study hospitals with pneumonia.
years) were more likely to fulfil this definition (p=0.012). 
Oxygen saturations were recorded for 812 (44.3%) chil-
dren and there was significant interhospital variation 
(range 9.9%–82.3%, median, 43.8%). Where oxygen 
saturations were recorded, the median value was 95% 
(IQR 90%–98%) and 180 (22.2%) had saturations below 
90%. Pallor was a common clinical finding—detected in 
340/1760 (19.3%) children. Pallor was observed more 
frequently in older children (aged 10–14 years, p≤0.001) 
and in high malaria transmission regions (226/816 
(27.7%) compared with 114/944 (12.1%) children in 
low-transmission regions (p≤0.001)). HIV status was 
determined to be positive in 9.9% of patients and was 
also found more frequently in older children (p≤0.001).
outcome analysis
Outcome information was available for 1825/1832 
(99.5%) patients, of which 145 (7.9%) died. Inpatient 
case fatality was higher in children aged 10–14 years. 
Univariate analysis indicated that mortality increased 
proportionate to the degree of pallor (table 4) with 
severe pallor (compared with none) associated with an 
OR for death of 9.57 (95% CI 5.94 to 15.41) and a pneu-
monia case fatality of 30.1%. Other clinical characteristics 
strongly associated with death in unadjusted analyses (OR 
>2) were: reduced consciousness, mild/moderate pallor; 
the inability to eat or drink; central cyanosis; severe pneu-
monia; oxygen saturations <90%; acidotic breathing and 
grunting. For comorbidities: acute neurological disorder; 
sepsis; HIV and severe malnutrition were strongly associ-
ated with death (OR >2), while malaria and sickle cell 
disease were not. Wheeze and asthma were protective.
In multivariate analyses (table 5), we adjusted for 
hospital, sex, age, respiratory rate >30/min and the pres-
ence of: central cyanosis, grunting, reduced conscious-
ness, inability to eat or drink, wheeze, crackles, pallor 
and indrawing (model 1). Difficulty breathing, acidotic 
breathing and convulsions were excluded due to collin-
earity with other variables. We excluded temperature and 
stridor, as neither had associations with death in univariate 
analysis. We were unable to include the data on oxygen 
saturation in our models, even after multiple imputation 
because the measurement of pulse oximetry was only 
recorded for 44.3% of children and varied substantially 
over time and between hospitals. This was due to incon-
sistency in availability of pulse oximeters as a result of 
factors such as damage, failure, loss or interrupted use 
in cases where they belonged to individual clinicians. 
Additional information pertaining to HIV status, malaria 
diagnosis and the presence of severe malnutrition were 
added in model 2. There was consistency in the point esti-
mates for the associations analysed in the multiple impu-
tation models and the complete case analysis (online 
supplementary table 2), so we have reported the find-
ings from the multiple imputation models to maximise 
use of the available data. The presence of severe pallor, 
reduced consciousness, mild/moderate pallor, central 
cyanosis and older age (>9 years) were strongly associated 
with death (adjusted OR (aOR) >2). Respiratory rate 
>30/min and inability to eat or drink were also signifi-
cantly associated with poor outcome. In model 2, HIV 
(aOR 2.31, 95% CI 1.39 to 3.84) and severe malnutrition 
(aOR 1.89, 95% CI 1.12 to 3.21) (model 2) were associ-
ated with mortality and malaria was not. In this model, 
central cyanosis and respiratory rate >30 lost significance 
in their association with death. In both models, sex and 
the presence of grunting, crackles and indrawing were 
not associated with mortality and wheeze was found to be 
protective, although not significantly.
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Table 3 Characteristics and comorbidities of children admitted to study hospitals with pneumonia
Characteristic
Age 5–9 years
n=1467*
Age 10–14 years
n=365* Total n=1832*
Demographic information
  Male 836/1461 (57.22%) 185/365 (50.68%) 1021/1826 (55.91%)
  Hospitals in high malaria transmission region 641/1467 (43.69%) 208/365 (56.99%) 849/1832 (46.34%)
  Referred to hospital 239/1214 (19.69%) 85/297 (28.62%) 324/1511 (21.44%)
  Readmitted to hospital 232/1232 (18.83%) 47/296 (15.88%) 279/1528 (18.26%)
Clinical characteristic
  Temperature ≥38°C 559/1321 (42.32%) 111/318 (34.91%) 670/1639 (40.88%)
  Respiratory rate >30/min 937/1216 (77.06%) 191/291 (65.64%) 1128/1507 (74.85%)
  Central cyanosis 24/1418 (1.69%) 1/353 (0.28%) 25/1771 (1.41%)
  Grunting 232/1394 (16.64%) 39/348 (11.21%) 271/1742 (15.56%)
  Acidotic breathing 58/1382 (4.2%) 12/350 (3.43%) 70/1732 (4.04%)
  Reduced consciousness 108/1400 (7.71%) 23/348 (6.61%) 131/1748 (7.49%)
  Cannot eat or drink 235/1347 (17.45%) 62/332 (18.67%) 297/1679 (17.69%)
  Stridor 46/1356 (3.39%) 12/342 (3.51%) 58/1698 (3.42%)
  Difficulty breathing 743/1416 (52.47%) 159/352 (45.17%) 902/1768 (51.02%)
  Wheeze 189/1396 (13.54%) 34/350 (9.71%) 223/1746 (12.77%)
  Crackles 504/1387 (36.34%) 109/351 (31.05%) 613/1738 (35.27%)
  Severe pallor 89/1411 (6.31%) 26/349 (7.45%) 115/1760 (6.53%)
  Mild/moderate pallor 158/1411 (11.2%) 67/349 (19.2%) 225/1760 (12.78%)
  No pallor 1164/1411 (82.49%) 256/349 (73.35%) 1420/1760 (80.68%)
  Chest wall indrawing 609/1400 (43.5%) 102/349 (29.23%) 711/1749 (40.65%)
  Convulsions 212/1406 (15.08%) 42/347 (12.1%) 254/1753 (14.49%)
  Oxygen saturation <90% 151/661 (22.84%) 29/151 (19.21%) 180/812 (22.17%)
  Mid-upper arm circumference <115 mm 41/620 (6.61%) 6/113 (5.31%) 47/733 (6.41%)
  Severe pneumonia 492/1443 (34.1%) 96/356 (26.97%) 588/1799 (32.68%)
Comorbidity
  HIV positive 122/1467 (8.32%) 60/365 (16.44%) 182/1832 (9.93%)
  Malaria diagnosed 422/1467 (28.77%) 123/365 (33.7%) 545/1832 (29.75%)
  Severe malnutrition 139/1467 (9.48%) 38/365 (10.41%) 177/1832 (9.66%)
  Sickle cell disease 41/1467 (2.79%) 12/365 (3.29%) 53/1832 (2.89%)
  Asthma 160/1467 (10.91%) 35/365 (9.59%) 195/1832 (10.64%)
  Cardiac disease 15/1467 (1.02%) 10/365 (2.74%) 25/1832 (1.36%)
  Genitourinary disease 10/1467 (0.68%) 5/365 (1.37%) 15/1832 (0.82%)
  Diabetes 3/1467 (0.2%) 1/365 (0.27%) 4/1832 (0.22%)
  Neurological disorder 116/1467 (7.91%) 18/365 (4.93%) 134/1832 (7.31%)
  Sepsis 8/1467 (0.55%) 1/365 (0.27%) 9/1832 (0.49%)
  Diarrhoea and dehydration 79/1467 (5.39%) 25/365 (6.85%) 104/1832 (5.68%)
  Acute neurological disorder 158/1467 (10.77%) 39/365 (10.68%) 197/1832 (10.75%)
*Denominators less than these values indicate missing data.
Pallor (any degree) performed better than all other 
individual clinical signs (AUC 0.69, 95% CI 0.64 to 0.74) 
in predicting mortality, and generally, the presence of 
individual clinical signs was a poor predictor of death 
(AUC range 0.51–0.69) (online supplementary table 1). 
Simple combinations of pallor with other clinical signs 
that had strong correlation with poor outcome improved 
the predictive performance: for example, pallor and/or 
reduced consciousness (AUC 0.73, 95% CI 0.69 to 0.78) 
and pallor and/or reduced consciousness and/or central 
cyanosis (AUC 0.74, 95% CI 0.69 to 0.79).
subgroup analyses
In model 3 (online supplementary material), we examined 
the subset of children aged 5–10 years (n=1585) for whom 
we were able to calculate WAZ scores (n=1496) and found 
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Table 4 Univariate associations for mortality among all children admitted to the study hospitals with pneumonia
Characteristic
Number of deaths/
number of patients Mortality OR (95% CI) P value
Age 10–14 years 51/363 14.05% 2.38 (1.66 to 3.42) <0.001
Age 5–9 years 94/1462 6.43%     
Male 75/1019 7.36% 0.83 (0.59 to 1.16) 0.318
Female 70/800 8.75%     
High malaria transmission region 85/846 10.05% 1.71 (1.21 to 2.41) 0.003
Low malaria transmission region 60/979 6.13%     
Referred 48/322 14.91% 2.63 (1.78, 3.86) <0.001
Not referred 74/1183 6.26%     
Readmitted 13/279 4.66% 0.55 (0.31 to 1.00) 0.063
Not readmitted 101/1243 8.13%     
Temperature ≥38.0°C 47/667 7.05% 0.94 (0.64 to 1.38) 0.83
Temperature <38.0°C 72/966 7.45%     
Respiratory rate >30 94/1126 8.35% 1.92 (1.13 to 3.27) 0.019
Respiratory rate ≤30 17/376 4.52%     
Central cyanosis 5/25 20% 3.20 (1.18 to 8.67) 0.033
No central cyanosis 126/1739 7.25%     
Grunting 35/270 12.96% 2.15 (1.42 to 3.24) <0.001
No grunting 95/1465 6.48%     
Acidotic breathing 10/70 14.29% 2.21 (1.10 to 4.43) 0.04
No acidotic breathing 116/1655 7.01%     
Reduced consciousness 37/128 28.91% 6.65 (4.30 to 10.27) <0.001
Alert 93/1613 5.77%     
Cannot eat or drink 47/296 15.88% 3.42 (2.31 to 5.07) <0.001
Can eat and drink 72/1378 5.22%     
Stridor 7/58 12.07% 1.75 (0.78 to 3.93) 0.268
No stridor 119/1633 7.29%     
Difficulty breathing 82/900 9.11% 1.47 (1.03 to 2.10) 0.04
No difficulty breathing 55/862 6.38%     
Wheeze 8/223 3.59% 0.43 (0.20 to 0.88) 0.026
No wheeze 122/1516 8.05%     
Crackles 59/613 9.62% 1.59 (1.11 to 2.29) 0.014
No crackles 70/1118 6.26%     
Severe pallor 34/113 30.09% 9.57 (5.94 to 15.41) <0.001
Mild/Moderate pallor 40/224 17.86% 4.83 (3.15 to 7.41) <0.001
No pallor 61/1417 4.30% 1   
Chest wall indrawing 65/711 9.14% 1.45 (1.01 to 2.07) 0.05
No chest wall indrawing 67/1031 6.50%     
Convulsions 37/252 14.68% 2.48 (1.65 to 3.72) <0.001
No convulsions 97/1495 6.49%     
Oxygen saturations <90% 25/179 13.97% 2.76 (1.61 to 4.76) <0.001
Oxygen saturations ≥90% 35/631 5.55%     
Mid-upper arm circumference <115 mm 8/47 17.02% 3.81 (1.66 to 8.77) 0.002
Mid-upper arm circumference <115 mm 35/685 5.11%     
Severe pneumonia 77/583 13.21% 2.86 (2.01 to 4.07) <0.001
Continued
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Characteristic
Number of deaths/
number of patients Mortality OR (95% CI) P value
Non-severe pneumonia 61/1209 5.05%     
HIV positive 33/181 18.23% 3.05 (2.00 to 4.66) <0.001
Not HIV positive 112/1644 6.81%     
Malaria diagnosed 48/542 8.86% 1.19 (0.83 to 1.71) 0.401
No malaria diagnosed 97/1283 7.56%     
Severe malnutrition 30/177 16.95% 2.72 (1.76 to 4.21) <0.001
No severe malnutrition 115/1648 6.98%     
Sickle cell disease 7/53 13.21% 1.80 (0.80 to 4.07) 0.238
No sickle cell disease 138/1772 7.79%     
Asthma 2/195 1.03% 0.11 (0.03 to 0.44) <0.001
No asthma 143/1630 8.77%     
Cardiac disease 5/25 20% 2.96 (1.10 to 8.02) 0.043
No cardiac disease 140/1800 7.78%     
Renal disease 2/15 13.33% 1.79 (0.40 to 8.03) 0.337
No renal disease 143/1810 7.90%     
Diabetes 1/4 25% 3.88 (0.40 to 37.56) 0.282
No diabetes 144/1821 7.91%     
Chronic neurological disorder 7/134 5.22% 0.62 (0.28 to 1.35) 0.296
No chronic neurological disorder 138/1691 8.16%     
Sepsis 3/9 33.33% 5.89 (1.46 to 23.82) 0.029
No sepsis 142/1816 7.82%     
Diarrhoea with dehydration 14/104 13.46% 1.89 (1.05 to 3.41) 0.051
No diarrhoea with dehydration 131/1721 7.61%     
Acute neurological disorder 53/194 27.32% 6.29 (4.30 to 9.19) <0.001
No acute neurological disorder 92/1631 5.64%     
Table 4 Continued
that a score of ≤−3 SD was associated with mortality (aOR 
2.99, 95% CI 1.61 to 5.55). Other factors associated with 
death were consistent with the findings shown in models 
1 and 2. In a sensitivity analysis of children admitted to 
hospitals in regions of low malaria endemicity, where 
malaria is unlikely to account for anaemia, we found that 
severe pallor and mild/moderate pallor were still signifi-
cantly associated with mortality (aOR 12.12, 95% CI 4.12 
to 35.67 and aOR 2.65, 95% CI 1.09 to 6.43, respectively) 
(model 4, online supplementary material).
Antibiotic treatment
There were 3172 documented antibiotic prescriptions for 
1725 children on admission, with 22 different antibiotics 
used (online supplementary table 3). The most frequently 
prescribed antimicrobials were intravenous penicillin 
(1291 prescriptions), intravenous aminoglycosides (879), 
intravenous cephalosporins (430) and oral amoxicillin 
(247) often in combinations. Over 98% of children were 
prescribed at least one of these four drugs (figure 3) and 
85% were prescribed at least one of the WHO first-line 
drugs (table 1). Excluding children with HIV or severe 
malnutrition and those who were re-admitted or referred 
(who may not typically get first-line antibiotic regimens) 
there were 1057 children, of whom 523 (49.5%) were 
treated in keeping with WHO under 5 guidance: penicillin 
and gentamicin for severe pneumonia; amoxicillin or peni-
cillin for non-severe pneumonia.
dIsCussIon
Mortality
Children aged 5–14 years with pneumonia accounted 
for 11.7% of all medical admissions to the study hospi-
tals for children aged >5 and<15 years. Overall, we found 
that mortality was high (7.9%) in this group. There 
were more admissions and deaths in children aged 5–9 
years, but there was higher case fatality among those 
aged 10–14 years (14.1%). Pneumonia case fatality 
rates (CFRs) have not been reported before in these 
age groups and, perhaps surprisingly they are similar to 
those reported in hospital-based pneumonia studies of 
children under 5 years: studies from sub-Saharan Africa 
report rates ranging from 5% to 10.4%.18 21–25 These 
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Table 5 Multivariate models for risk factors for mortality for all pneumonia cases (with multiple imputation)
Variable
Model 1 Model 2
OR 95% CI P value OR 95% CI P value
Sex: male 0.87 0.6 to 1.27 0.477 0.84 0.57 to 1.23 0.362
Age: >9 2.78 1.83 to 4.24 <0.001 2.48 1.62 to 3.80 <0.001
Respiratory rate: >30 1.87 1.02 to 3.43 0.044 1.67 0.94 to 2.98 0.083
Cyanosis: true 3.27 1.03 to 10.43 0.045 2.89 0.86 to 9.75 0.086
Grunting: true 1.48 0.89 to 2.49 0.134 1.69 0.99 to 2.88 0.054
Reduced consciousness: true 3.65 2.07 to 6.44 <0.001 4.18 2.34 to 7.47 <0.001
Cannot eat or drink: true 1.82 1.13 to 2.93 0.013 1.91 1.17 to 3.13 0.01
Wheeze: true 0.52 0.23 to 1.16 0.107 0.55 0.24 to 1.3 0.172
Crackles: true 1.42 0.93 to 2.17 0.101 1.3 0.83 to 2.03 0.255
Pallor: severe 8.06 4.72 to 13.75 <0.001 7.4 4.28 to 12.8 <0.001
Pallor: mild/moderate 3.5 2.19 to 5.6 <0.001 2.96 1.83 to 4.79 <0.001
Indrawing: true 1.34 0.85 to 2.1 0.211 1.2 0.77 to 1.89 0.42
HIV: positive – – – 2.31 1.39 to 3.84 0.001
Malaria: positive – – – 0.81 0.49 to 1.32 0.386
Severe malnutrition: present – – – 1.89 1.12 to 3.21 0.018
Figure 3 Proportion of children with pneumonia in the 
study hospitals who were prescribed at least one of the top 
four most frequently prescribed antibiotics on admission to 
hospital (n=1725).
include pneumonia mortality rates from studies within 
the CIN: for children aged between 2 and 59 months one 
study reported CFR of 5.9%,21 and another reported 5%, 
the latter excluded children with severe acute malnutri-
tion, meningitis and HIV.18
These higher than expected CFRs could be explained 
by several factors: (1) late presentation to hospital,26 27 
(2) different admission thresholds or inadequate guid-
ance for primary care workers on what constitutes severe 
illness in this age group. This may contribute to late 
presentation or could result in only the highest-risk chil-
dren being admitted—there were low absolute number of 
children admitted (especially in those aged 10–14 years) 
if we consider that the general population cohort is the 
same size as for under 5s, (3) residual pneumococcal 
disease—pneumococcal vaccination was only introduced 
in Kenya in 2011, therefore the majority of children in 
our study would not have been immunised making them 
more susceptible to invasive disease,28 although they are 
likely to have benefited from herd immunity,29 (4) a wider 
range of pneumonia pathogens that are not susceptible 
to commonly used antibiotics and (5) a high proportion 
of children with comorbidities such as HIV or underlying 
chronic illness (including some that may not be detected 
due to weak diagnostic capacity).
Clinical risk factors
The characteristics associated with mortality in our study: 
pallor (any), central cyanosis, reduced consciousness, 
tachypnoea, inability to eat or drink, HIV and severe 
malnutrition are broadly similar to those described in 
studies for children under 5 years. Pallor stood out from 
other individual characteristics in the strength of its asso-
ciation with death. It is a widely accepted clinical tool used 
to identify children with moderate and severe anaemia in 
resource-limited settings (although the majority of the 
data supporting its use are derived from studies in under 
5s).30–33 This association with mortality has previously 
been shown for children under 5 years but never before 
in older children.18 22 34 35 Children in our cohort may 
be anaemic for a number of reasons: haemolysis due to 
malaria, 30 atypical infection or sepsis; myelosuppression 
related to malaria and co-infection with non-typhoidal 
salmonellae36; nutritional deficiency or other comorbid-
ities such as HIV, sickle cell and malignancy. However, 
the relationship between anaemia, pneumonia and high 
mortality is less clear. Does the presence of anaemia 
simply represent children with comorbidities or those 
living in extreme poverty or neglect—children for whom 
we might expect worse health outcomes? In our analysis, 
socioeconomic factors were not accounted for. Chil-
dren may also have been referred to these higher-level 
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facilities specifically for blood transfusion, therefore 
anaemic children may be over-represented in our study 
cohort. However, the fact that even mild forms of clin-
ical pallor remained associated with death counters this. 
Alternatively, there may be a specific physiological rela-
tionship between anaemia and respiratory compromise 
that affects clinical outcome. For example, in the context 
of pneumonia, anaemia might compound respiratory 
compromise further by reducing the oxygen carrying 
capacity of red blood cells.37 Finally, severe anaemia itself 
is a well-recognised cause of respiratory distress, there-
fore it is possible that children in our study were misdiag-
nosed with pneumonia. Again, the association of mild/
moderate anaemia with death counters this. It is likely 
that the role of anaemia is complex and multifactorial 
and this relationship warrants further study.
Our initial analysis shows that both individual and 
simple combinations of clinical signs do not have good 
sensitivity or specificity in predicting clinical outcome 
among hospitalised over 5s with pneumonia (online 
supplementary table 1). For example, the combination of 
clinical characteristics used to define severe pneumonia 
by WHO in the under 5s was poor in discriminating 
those at risk of death (sensitivity: 0.56, specificity: 0.68 
and AUC: 0.62). Any pallor (AUC 0.69), or combinations 
of pallor and/or reduced consciousness (AUC 0.73) or 
pallor and/or reduced consciousness and/or central 
cyanosis (AUC 0.74) performed better than having 
‘severe pneumonia’. However, in our data mortality was 
high in children without signs of severe disease (5.1%), 
severe pneumonia was observed more frequently in chil-
dren aged 5–9 years—the group with lower mortality—
and we have no data on the clinical signs among similarly 
aged outpatient children presenting with possible pneu-
monia. Further work is therefore needed to explore and 
then test which clinical signs may be useful in identifying 
high-risk children among those presenting with possible 
pneumonia at ages 5–14 years.
Human immunodeficiency virus
HIV tests were ordered in 1027 (56.1%) children. The 
proportion with a confirmed diagnosis was high, particu-
larly in those >9 where 16.4% were HIV positive. This is 
much higher than population prevalence rates reported 
in Kenya, which are estimated at 0.9% for children aged 
18 months to 14 years.38 The high rates we observed could 
be because pneumonia disproportionately affects patients 
with HIV.39 40 However, it is also plausible that population 
prevalence of HIV is higher in this older population—they 
are less likely to have benefited from prevention of mother-
to-child transmission programmes (first officially launched 
in Kenya in 2002), and may have some risk of HIV acqui-
sition through sexual transmission. In our cohort HIV 
was associated with death, which is consistent with other 
studies.41 Factors that might contribute to poor outcome 
in these HIV-infected children include complex sociocul-
tural issues around stigma and disclosure and access to 
and retention in care. Unfortunately, our routine dataset 
does not allow us to determine whether these children 
are enrolled in HIV care and treatment programmes nor 
provide information on markers of immune function such 
as CD4 count and viral load.
Treatment
In our study, the majority (85%) of children who were 
prescribed an antibiotic on admission were prescribed 
at least one of the first-line antibiotics recommended by 
the current WHO pneumonia case management guide-
lines. This may indicate that clinicians treat children over 
5 years as they do those under 5 years (who represent 
the majority of pneumonia cases that they see), or that 
clinicians do reference the under 5 guidelines when 
treating older children. These prescribing practices are 
also likely to be reinforced by factors such as the low cost 
and availability of these drugs, clinician experience and 
familiarity using them,42 and regular audit and feedback 
against national protocols (for under 5s).12 However, 
these treatments do not adequately target organisms 
which can cause complicated pneumonia such as Staph-
ylococcus aureus or atypical pathogens such as Mycoplasma 
pneumoniae. There is some evidence to suggest that over 
5s are more likely to present with atypical infections, 
these studies are from high-income settings with small 
sample sizes.7
The lack of robust evidence on pneumonia aetiology 
in this age group means that best practice with regard 
to antibiotic treatment really is unknown. The recently 
completed Pneumonia Aetiology Research for Child 
Health study sought to refresh understanding of paedi-
atric pneumonia aetiology in LMICs, but focused exclu-
sively on under 5s.43 Unfortunately, we were unable to 
confirm aetiology in our study due to the limited diag-
nostic capacity of the study hospitals.8 There is an urgent 
need for carefully designed studies on the effectiveness 
of alternative antibiotics, as well as other supportive care 
regimens such as oxygen and blood transfusion,44 45 to 
guide the development of empirical treatment protocols 
for pneumonia in older children.
strengths and limitations
We collected data from routine clinical practice, repre-
senting real-life scenarios rather than a controlled 
research environment, and our large sample size was 
taken from multiple hospitals across Kenya. As a result, 
our data are the most representative to date of children 
aged 5–14 years admitted to district hospitals in sub-Sa-
haran Africa. To our knowledge, this is the first study 
that examines specifically for risk factors in over 5s in a 
resource-poor setting. We examined a complete 4-year 
period to reduce seasonal bias—an important considera-
tion in the context of respiratory infections.46
Our analysis is based on the documentation of clinical 
findings with retrospective data entry. This exposes the 
study to potential bias due to missing data—either due 
to gaps in medical documentation or misplaced hospital 
records. Considerable effort was taken to mitigate this 
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and ensure comprehensive sampling of high-quality 
data.9 This included immediate data entry at the point 
of discharge, regular audit of clinical records against 
hospital admission registers, training and supervision 
of data clerks, standardised patient admission forms 
for clinicians with regular feedback on their complete-
ness and dissemination of standard clinical guidelines 
to healthcare workers within the study hospitals. We also 
applied multiple imputation to address missing data and 
maximise the use of available data. Our CIN provides a 
suitable platform for a future prospective study exam-
ining the findings highlighted in this analysis while mini-
mising the limitations described above.
The observational nature of this study and use of data 
collected during routine care also presents limitations: 
the interpretation of clinical signs is likely to vary because 
characteristics are identified and recorded by a variety 
of junior clinicians.47 Although, arguably, this may also 
increase the generalisability of our findings. There is 
potential for misdiagnosis and misclassification because 
of limited access to diagnostic equipment. For example, 
the lack of pulse oximetry data in the study may have 
led to an underestimation of the utility of WHO severity 
classification. We were unable to account for the effect 
of antibiotic treatment on outcome because we only had 
information on prescriptions on admission which does not 
reflect what was actually administered, nor any changes 
to treatment made during admission. Similarly, we were 
unable to reliably assess the impact of quality of care and 
other unobserved factors that might influence manage-
ment decisions, such as the clinician’s gut feeling influ-
encing admission decisions.48
Finally, we did not have data on children managed as 
outpatients or in the community. This group is likely to 
represent the majority of over 5s with pneumonia and 
being able to compare the two groups would further 
elucidate risk factors for poor outcome. Future work 
should also focus on broader risk factors for death that 
have been highlighted in previous studies (for children 
under 5 years), these include low maternal education and 
other socioeconomic factors such as indoor pollution.41
ConClusIon
Children over 5 years are a neglected group with 
high inpatient pneumonia mortality. We have shown 
non-trivial risk in this population and that there is a 
need for research to explore the underlying factors that 
account for this, particularly in older children (aged 
10–14 years). Apparently important signs such as pallor 
or reduced consciousness are not included in the WHO 
criteria for classification of severity for under 5s and so 
directly extending this case management approach to 
over 5s does not seem appropriate. Greater attention 
may also need to be paid to comorbidity in these age 
groups, especially with HIV and severe malnutrition. 
Our data do not constitute formal evidence that using 
these patient features to indicate high risk of mortality, 
and thus alternative or aggressive treatments, would save 
lives. Rather our data make it clear that we need to better 
understand the characteristics of children presenting 
with possible pneumonia at all levels of the health system 
ideally linked to studies of aetiology. Furthermore, in 
the 5–14 years age group there is need to explore the 
aetiology and pathophysiology of anaemia among chil-
dren with respiratory distress; care-seeking behaviour 
and adequacy of health services delivery, broader soci-
oeconomic risk factors as well as exploring which inter-
ventions are most effective at improving outcomes. This 
agenda is important as we seek to implement universal 
health coverage that should span children of all ages.
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